⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8591106 | 0.83 | NPC1 (0.44) | — | |
| SCHEMBL31729646 | 0.82 | GBA1 (0.52) | — | |
| SCHEMBL3231706 | 0.82 | GBA1 (0.52) | — | |
| SCHEMBL14157125 | 0.81 | — | — | |
| SCHEMBL10461384 | 0.79 | GBA1 (0.48) | — | |
| SCHEMBL507025 | 0.78 | — | — | |
| SCHEMBL7433897 | 0.77 | GBA1 (0.42) | — | |
| SCHEMBL1816193 | 0.77 | GBA1 (0.47) | — | |
| SCHEMBL2358386 | 0.77 | GBA1 (0.47) | — | |
| SCHEMBL668445 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 285 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107177588-A | Modified glass bead carrier for fixing Azodrin degradation bacteria and preparation method thereof | 光合强化（北京）生物科技有限公司 | 2017-09-19 | — | — | CN | claimed |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20250333429-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| EP-4622981-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | Forward Therapeutics, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2025-09-25 | — | — | US | disclosed |
| US-12384808-B2 | Modulators of TNF-α activity | FORWARD THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-12264154-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-12239630-B2 | Carboxylic acid aromatic amides as antagonists of bradykinin B1 receptor | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-03-04 | — | — | US | disclosed |
| CN-115068468-B | Carboxylic aromatic amides as bradykinin B1 receptor antagonists | 拜耳制药股份公司 | 2025-02-25 | — | — | CN | disclosed |
| US-5714496-A | TREATMENT OF HYPERCHOLESTEROLEMIA AND ATHERSCLEROSIS | ZENECA LIMITED (GB) | 1998-02-03 | — | — | US | disclosed |
| WO-1998003484-A1 | SUBSTITUTED PYRIDINES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1998-01-29 | — | — | WO | disclosed |
| EP-0656897-B1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LTD (GB) | 1998-01-07 | — | — | EP | disclosed |
| EP-0796858-A1 | Triazole antifungal agents | Pfizer Limited (GB) | 1997-09-24 | — | — | EP | disclosed |
| WO-1997001552-A1 | TRIAZOLE ANTIFUNGAL AGENTS | PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. (IE) | 1997-01-16 | — | — | WO | disclosed |
| US-5541203-A | PREVENTING OR CURING FUNGAL INFECTIONS | PFIZER INC. (US) | 1996-07-30 | — | — | US | disclosed |
| EP-0656897-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LIMITED (GB) | 1995-06-14 | — | — | EP | disclosed |
| EP-0607193-A1 | TRIAZOLE ANTIFUNGAL AGENTS | Pfizer Limited (GB) | 1994-07-27 | — | — | EP | disclosed |
| WO-1994005660-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LIMITED (GB) | 1994-03-17 | — | — | WO | disclosed |
| WO-1993007139-A1 | TRIAZOLE ANTIFUNGAL AGENTS | PFIZER LIMITED (GB) | 1993-04-15 | — | — | WO | disclosed |